title: Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a significantly better survival rate than 10 patients transplanted with a conventional conditioning (4 in CR and 6 in non-CR) (3-year EFS (95% confidence interval): 80.0% (20.4-96.9%) vs. 10.0% (0.6%-35.8%), P = 0.039).
authors.affiliation: Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Muramatsu
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Takashi
authors.initials: T
authors.lastname: Taga
authors.forename: Ken
authors.initials: K
authors.lastname: Tabuchi
authors.forename: Souichi
authors.initials: S
authors.lastname: Adachi
authors.forename: Masami
authors.initials: M
authors.lastname: Inoue
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kitoh
authors.forename: Aiko
authors.initials: A
authors.lastname: Suminoe
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Yabe
authors.forename: Eichi
authors.initials: E
authors.lastname: Azuma
authors.forename: Yoko
authors.initials: Y
authors.lastname: Shioda
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ogawa
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Kinoshita
authors.forename: Hisato
authors.initials: H
authors.lastname: Kigasawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Osugi
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Koike
authors.forename: Keisei
authors.initials: K
authors.lastname: Kawa
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Atsuta
authors.forename: Kazuko
authors.initials: K
authors.lastname: Kudo
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
keywords: Down syndrome; acute myeloid leukemia; allogeneic stem cell transplantation; reduced intensity conditioning